Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats.

Transplant international : official journal of the European Society for Organ Transplantation·2006
Same author

[Effects of mechanical tensile stress on the expression of ICAM-1 mRNA in osteoblasts differentiated from rBMSCs].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2006
Same author

[Effects of osteoporosis on experimental tooth movement in aged rats].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2006
Same author

MCALIGN2: faster, accurate global pairwise alignment of non-coding DNA sequences based on explicit models of indel evolution.

BMC bioinformatics·2006
Same author

[Managements of masked mastoiditis].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2006
Same author

Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.

The Journal of biological chemistry·2006

Related Experiment Video

Updated: May 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Scientific considerations for assessing biosimilar products.

Shein-Chung Chow1, Jun Wang, Laszlo Endrenyi

  • 1Duke University School of Medicine, Durham, NC, U.S.A.

Statistics in Medicine
|August 31, 2012
PubMed
Summary

Assessing biosimilarity and interchangeability for follow-on biologics requires different criteria than generic drugs due to complex manufacturing. This study provides scientific considerations for evaluating biosimilar products effectively.

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Related Experiment Videos

Last Updated: May 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Area of Science:

  • Biopharmaceutical Science
  • Regulatory Science
  • Drug Development

Background:

  • Follow-on biologics, or biosimilar products, present unique challenges in assessment compared to generic drugs.
  • Fundamental differences in functional structures and manufacturing processes complicate biosimilar development.
  • Existing bioequivalence criteria for generics may not be suitable for biosimilarity assessment.

Purpose of the Study:

  • To address the complexities in assessing biosimilarity and drug interchangeability for follow-on biologics.
  • To propose scientific considerations for the criteria, design, and analysis of biosimilar product evaluation.
  • To discuss practical and scientific issues relevant to biosimilar product regulation.

Main Methods:

  • Review of scientific literature and regulatory guidelines.
  • Analysis of challenges specific to biosimilar product development and assessment.
  • Discussion of issues raised in public hearings and meetings concerning biosimilar products.

Main Results:

  • Standard bioequivalence methods for generics are insufficient for biosimilarity.
  • Specific scientific considerations are needed for biosimilarity and interchangeability assessment criteria.
  • Key scientific and practical issues from FDA discussions are highlighted.

Conclusions:

  • Novel approaches are required for evaluating biosimilarity and interchangeability.
  • The development of appropriate criteria and methods is crucial for biosimilar product approval.
  • Further scientific discourse and regulatory refinement are necessary for follow-on biologics.